Characterization of New Human Glioblastoma Cell Lines

Киселева, Л. Н.; Карташев, А. В.; Vartanyan, N. L.; Pinevich, A. A.; Филатов, М. В.; Самойлович, М. П.

doi:10.1134/s1990519x18010108

Cited by 12 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell line T98G is a very well studied model of cancer research usually used in drug screening and molecular GB experimental models. The cells manifest major glioblastoma properties and exhibit the typical expression profi le for mesenchymal and growth factor genes (33).…”

Section: Discussionmentioning

confidence: 99%

The effect of temozolomide on apoptosis-related gene expression changes in glioblastoma cells

Vidomanová¹,

Majerčíková²,

Dibdiaková³

et al. 2022

BLL

View full text Add to dashboard Cite

BACKGROUND: Glioblastoma (GB) is the most common and biologically the most aggressive primary brain tumor of the central nervous system (CNS) in adults. Standard treatment for newly diagnosed GB consists of surgical resection, radiotherapy, and chemotherapy with temozolomide (TMZ). Despite numbers of studies, a resistance to chemotherapy is the major obstacle to successful GB treatment. OBJECTIVES: The aim of our study was to detect the sensitivity of glioblastoma T98G cells to TMZ treatment and subsequently to determine the expression changes of apoptosis-associated genes in glioblastoma cells. MATERIAL AND METHODS: The human glioblastoma cell line (T98G) was treated with specifi ed concentrations of TMZ during different time periods. Their viability was measured by colorimetric MTT assay and the activation of the apoptotic pathway was determined by measuring the caspase 3/7 activity. Commercial pre-designed microfl uidic array was used to quantify expression of human apoptosis-associated genes. RESULTS: The untreated control of T98G cell line against human brain total RNA standards reported signifi cant changes in several apoptotic genes expression levels. We identifi ed also a deregulation in gene expression levels between the TMZ treated and untreated T98G cells associated with apoptotic pathways. After 48 hours of exposure of T98G cells to TMZ, we observed a signifi cant deregulation of seven genes: BBC3, BCL2L1, RIPK1, CASP3, BIRC2, CARD6 and DAPK1. These results can contribute to the importance of apoptosis in glioblastoma cells metabolism and effect of TMZ treatment. CONCLUSIONS: Identifi cation of apoptotic gene panel in T98G cell line could help to improve understanding of brain tumor cells metabolism. Recognizing of the pro-apoptotic and anti-apoptotic genes expression changes could contribute to clarify the sensitivity to TMZ therapy and molecular base in healthy and tumor cells (Tab. 1, Fig. 2, Ref. 48).

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of temozolomide on apoptosis-related gene expression changes in glioblastoma cells

Vidomanová¹,

Majerčíková²,

Dibdiaková³

et al. 2022

BLL

View full text Add to dashboard Cite

show abstract

“…Of note are recent studies that demonstrate that newly derived human GBM cells have similar gene expression patterns to the T98G that was developed over 50 years ago. These data suggest that the transformed cellular phenotype is relatively stable from the time of initiation and that time in culture is less deleterious to the original tumor gene expression phenotype than was once thought [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

RNA Sequencing in Hypoxia-Adapted T98G Glioblastoma Cells Provides Supportive Evidence for IRE1 as a Potential Therapeutic Target

White

Liu

Hákonarson

et al. 2023

Genes

View full text Add to dashboard Cite

Glioblastoma (GBM) is an aggressive brain cancer with a median survival time of 14.6 months after diagnosis. GBM cells have altered metabolism and exhibit the Warburg effect, preferentially producing lactate under aerobic conditions. After standard-of-care treatment for GBM, there is an almost 100% recurrence rate. Hypoxia-adapted, treatment-resistant GBM stem-like cells are thought to drive this high recurrence rate. We used human T98G GBM cells as a model to identify differential gene expression induced by hypoxia and to search for potential therapeutic targets of hypoxia adapted GBM cells. RNA sequencing (RNAseq) and bioinformatics were used to identify differentially expressed genes (DEGs) and cellular pathways affected by hypoxia. We also examined expression of lactate dehydrogenase (LDH) genes using qRT-PCR and zymography as LDH dysregulation is a feature of many cancers. We found 2630 DEGs significantly altered by hypoxia (p < 0.05), 1241 upregulated in hypoxia and 1389 upregulated in normoxia. Hypoxia DEGs were highest in pathways related to glycolysis, hypoxia response, cell adhesion and notably the endoplasmic reticulum, including the inositol-requiring enzyme 1 (IRE1)-mediated unfolded protein response (UPR). These results, paired with numerous published preclinical data, provide additional evidence that inhibition of the IRE1-mediated UPR may have therapeutic potential in treating GBM. We propose a possible drug repurposing strategy to simultaneously target IRE1 and the spleen tyrosine kinase (SYK) in patients with GBM.

show abstract

“…In vitro cultures of GBM cell lines have been widely used as an important model for understanding GMB heterogeneity, drug sensitivity and resistance, evaluation of new therapeutic approaches and to search for novel biomarkers [16][17][18][19][20]. The Human Glioblastoma Cell Culture (HGCC) biobank has assembled a panel of 53 cell lines derived from surgical samples of GBM patients [21].…”

Section: Introductionmentioning

confidence: 99%

Genomic and Transcriptomic Characterization of the New Human Glioblastoma Cell Line AHOL1

Ferreira¹,

Amorim²,

Burbano³

et al. 2019

Preprint

View full text Add to dashboard Cite

Cancer cell lines are widely used as in vitro models of tumorigenesis, facilitating fundamental discoveries in cancer biology and translational medicine. Currently, there are few options for glioblastoma (GBM) treatment and limited in vitro models with accurate genomic and transcriptomic characterization. Here, a detailed characterization of a new GBM cell line, namely AHOL1, was conducted in order to fully characterize its molecular composition based on its copy number alteration (CNA) and transcriptome profiling, followed by the validation of key elements associated with GBM tumorigenesis. Large numbers of CNAs and differentially expressed genes (DEGs) were identified. CNAs were distributed throughout the genome, including gains at Xq11.1-q28, Xp22.33-p11.1, Xq21.1-q21.33, 4p15.1-p14, 8q23.2-q23.3 and losses at Yq11.21-q12, Yp11.31-p11.2 and 12p13.31 positions. Nine druggable genes were identified, including HCRTR2, ETV1, PTPRD, PRKX, STS, RPS6KA6, ZFY, USP9Y and KDM5D. By integrating DEGs and CNAs, we identified 57 overlapping genes enriched in fourteen pathways. Altered expression of several cancer-related candidates found in the DEGs-CNA dataset was confirmed by RT-qPCR. Taken together, this first comprehensive genomic and transcriptomic landscape of AHOL1 provides unique resources for further studies and identifies several druggable targets that may be useful for therapeutics and biologic and molecular investigation of GBM.

show abstract

Characterization of New Human Glioblastoma Cell Lines

Cited by 12 publications

References 8 publications

The effect of temozolomide on apoptosis-related gene expression changes in glioblastoma cells

The effect of temozolomide on apoptosis-related gene expression changes in glioblastoma cells

RNA Sequencing in Hypoxia-Adapted T98G Glioblastoma Cells Provides Supportive Evidence for IRE1 as a Potential Therapeutic Target

Genomic and Transcriptomic Characterization of the New Human Glioblastoma Cell Line AHOL1

Contact Info

Product

Resources

About